Brent Duncan

Developing economical, easy-to-use tools, designed by clinicians, that help get patients back to normal life quickly and safely.

A mission equal parts scientific and humanitarian. CerSci Therapeutics is a clinical-stage biotechnology company developing non-opioid pharmaceuticals for the treatment of pain. With a focus on alleviating human suffering and rescuing society from the on-going opioid crisis, CerSci is poised to deliver a new generation of non-opioid medicines to treat acute postoperative pain and chronic neuropathic pain (e.g. painful diabetic neuropathy). CerSci's lead clinical candidate, CT-044, is currently in Phase I Safety and Tolerability Studies in human volunteers (Phase I).

Developing economical, easy-to-use tools, designed by clinicians, that help get patients back to normal life quickly and safely.

Dr. Ted Price leads an academic neuroscience research team at the University of Texas at Dallas. Their work led to a breakthrough in the field of pain research. And that breakthrough led directly to Ted’s™ Pain Cream. You probably have heard of resveratrol, the powerful anti-aging molecule found in red wine (ours comes from japanese knotweed, but it’s the same stuff). Well it turns out resveratrol may do a lot more than just keep away wrinkles. Here’s where salicylic acid comes in (which we get from wintergreen plants, hence the minty fragrance of our cream). Salicylic acid might be the oldest pain reliever known to humans. But combine it with resveratrol, put it on something that hurts, suddenly, by all appearances, there’s brand new, very exciting chemistry happening. All with nothing but two simple, nature-made products.

A mission equal parts scientific and humanitarian. CerSci Therapeutics is a clinical-stage biotechnology company developing non-opioid pharmaceuticals for the treatment of pain. With a focus on alleviating human suffering and rescuing society from the on-going opioid crisis, CerSci is poised to deliver a new generation of non-opioid medicines to treat acute postoperative pain and chronic neuropathic pain (e.g. painful diabetic neuropathy). CerSci's lead clinical candidate, CT-044, is currently in Phase I Safety and Tolerability Studies in human volunteers (Phase I).

Adaptive3D is the premium additive manufacturing polymer resin supplier.  We partner with global leaders to deliver solutions for functional end use products and prototypes. Founded by inventor Walter Voit PhD in Dallas Texas, Adaptive3D is rapidly advancing to fulfill his vision of enabling high volume additive manufacturing through optimized materials. The core chemistry was originally developed through a project funded by the Defense Advanced Research Agency (DARPA), and the company is the recipient of a highly competitive Small Business Innovation Research grant from the National Science Foundation. Adaptive3D offers additive manufacturing polymer resins and specialty polymers to a range of industries around the world. The company is already fulfilling its mission of partnering with global leaders by securing partnerships with Fortune 500 companies. In particular the company leads in the area of rubber-like 3D printable materials, damping materials, and low-cure stress photopolymers.